Skip to main content
Premium Trial:

Request an Annual Quote

Leica, RareCyte to Co-Market CTC Technologies

NEW YORK (GenomeWeb) – Danaher's Leica Biosystems and RareCyte recently announced a co-marketing agreement covering Leica's Bond RX research staining platform and RareCyte's AccuCyte CyteFinder rare cell analysis product. 

According to the companies, the deal will provide researchers a fully automated solution for immunostaining captured circulating tumor cells deposited on microscope slides. The Bond RX platform is an open and flexible system that provides a high-throughput workflow. RareCyte's AccuCyte CyteFinder is an automated image analysis platform that enables the analysis of cells in up to six immunofluorescence channels. The combination of the technologies will accelerate the development of clinical applications for CTCs, the partners said. 

"This will enable us to provide an integrated platform that combines rare cell identification and single-cell analysis capability," RareCyte CEO Ron Seubert said in a statement, adding the deal will make CTC analysis widely available to the scientific and diagnostics research community. 

Financial and other terms of the deal were not disclosed.